Last reviewed · How we verify

Del Nido

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · FDA-approved active Small molecule

Del Nido cardioplegia is a cold crystalloid solution that rapidly cools and arrests the heart during cardiac surgery by delivering potassium and other electrolytes to stop myocardial contractions.

Del Nido cardioplegia is a cold crystalloid solution that rapidly cools and arrests the heart during cardiac surgery by delivering potassium and other electrolytes to stop myocardial contractions. Used for Myocardial protection during cardiac surgery requiring cardiopulmonary bypass.

At a glance

Generic nameDel Nido
SponsorFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Drug classCardioplegic solution
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Del Nido solution is a modified cardioplegic agent used during cardiopulmonary bypass to induce cardiac arrest and provide myocardial protection during open-heart surgery. It combines a single-dose potassium-based crystalloid formulation with additives including lidocaine, magnesium, and dextrose to reduce ischemic injury and improve post-operative cardiac function. The solution allows surgeons extended operative time (up to 3-4 hours) with a single administration, compared to traditional multi-dose cardioplegia protocols.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: